DexCom
DXCM
415 hedge funds and large institutions have $10.6B invested in DexCom in 2018 Q4 according to their latest regulatory filings, with 105 funds opening new positions, 153 increasing their positions, 118 reducing their positions, and 52 closing their positions.
102% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 52
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
30% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 118
14% more funds holding
Funds holding: 364 → 415 (+51)
3% less call options, than puts
Call options by funds: $25.8M | Put options by funds: $26.7M
4.33% less ownership
Funds ownership: 401.9% → 397.57% (-4.3%)
17% less capital invested
Capital invested by funds: $12.7B → $10.6B (-$2.13B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$231M |
| 2 |
HM
HealthCor Management
New York
|
+$126M |
| 3 |
BlackRock
New York
|
+$117M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89.4M |
| 5 |
Two Sigma Advisers
New York
|
+$82.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$501M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$242M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$166M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$93.2M |
| 5 |
O
OppenheimerFunds
New York
|
-$88.2M |
DXCM Hedge Fund Activity: Q4 2018 in Review
415 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q4 2018, worth a combined $10.6B — down 17% from $12.7B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new DXCM positions and 52 closed out — a net gain of 53 holders — while 153 added to existing stakes and 118 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $231M. The largest seller was T. Rowe Price Associates, cutting an estimated $501M.
- 415 institutional investors held DexCom (DXCM) as of Q4 2018, up from 364 in Q3 2018.
- Funds reported $10.6B of DexCom stock for Q4 2018, down 17% quarter-over-quarter.
- 105 funds opened new DexCom positions in Q4 2018 and 52 closed out, a net change of +53 holders.
- The largest DexCom buyer in Q4 2018 was JP Morgan Chase, an estimated $231M added.
- The largest DexCom seller in Q4 2018 was T. Rowe Price Associates, an estimated $501M sold.
Based on aggregated 13F filings for Q4 2018.